Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05632393 · ClinicalTrials.gov registry record · Phase 1
A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
A Phase 1 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05632393: Completed Phase 1 study, sponsored by Idorsia Pharmaceuticals.
NCT05632393 is a Phase 1 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05632393, a Phase 1 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A study to measure daridorexant in breast milk of healthy lactating women
Primary Outcome
Cumulative amount excreted in breast milk over the collection time
Interventions
- DRUG Daridorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2023-04-30 |
| Phase | Phase 1 |
What the finished NCT05632393 record still lists
NCT05632393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Daridorexant is the first listed.
NCT05632393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05632393 about?
NCT05632393 is a clinical study titled "A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women". A study to measure daridorexant in breast milk of healthy lactating women
What is the current status of trial NCT05632393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-01-16. Estimated completion is 2023-04-30.
What interventions are being tested in trial NCT05632393?
The interventions under investigation include: Daridorexant (DRUG).
Who is sponsoring clinical trial NCT05632393?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05632393's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI